{"abstract":"The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Determining Whether to Submit an ANDA or a 505(b)(2) Application.\" This guidance is intended to serve as a foundational guidance to assist applicants in determining which one of the abbreviated approval pathways under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) is appropriate for the submission of a marketing application to FDA.","action":"Notice of availability.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/10/13/2017-22196.html","cfr_references":[],"citation":"82 FR 47749","comment_url":null,"comments_close_on":"2017-12-12","correction_of":null,"corrections":[],"dates":"Submit either electronic or written comments on the draft guidance by December 12, 2017 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.","disposition_notes":null,"docket_ids":["Docket No. FDA-2017-D-5974"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":2,"comment_start_date":"2017-10-13","updated_at":"2023-02-28T15:20:00.540-05:00","comment_url":"https://www.regulations.gov/commenton/FDA-2017-D-5974-0001","allow_late_comments":null,"id":"FDA-2017-D-5974-0001","comment_end_date":"2017-12-13","regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2017-D-5974","title":"Determining Whether to Submit an ANDA or a 505(b)(2) Application; Draft Guidance for Industry; Availability"}],"document_number":"2017-22196","effective_on":null,"end_page":47750,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/10/13/2017-22196.xml","html_url":"https://www.federalregister.gov/documents/2017/10/13/2017-22196/determining-whether-to-submit-an-abbreviated-new-drug-application-or-a-505b2-application-draft","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-22196?publication_date=2017-10-13","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-10-13/2017-22196/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":454,"last_updated":"2026-11-22 16:15:03 -0500"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-10-13/pdf/2017-22196.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-22196.pdf?1507812366","publication_date":"2017-10-13","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/10/13/2017-22196.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":2,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2017-D-5974","supporting_documents_count":0,"docket_id":"FDA-2017-D-5974","document_id":"FDA-2017-D-5974-0001","regulation_id_number":null,"title":"Determining Whether to Submit an ANDA or a 505(b)(2) Application; Draft Guidance for Industry; Availability ","checked_regulationsdotgov_at":"2023-02-28T20:19:59Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":47749,"subtype":null,"title":"\"Determining Whether To Submit an Abbreviated New Drug Application or a 505(b)(2) Application;\" Draft Guidance for Industry; Availability","toc_doc":"Determining Whether to Submit an Abbreviated New Drug Application or a 505(b)(2) Application","toc_subject":"Guidance:","topics":[],"type":"Notice","volume":82}